VYNE Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

BRIDGEWATER, N.J., Nov. 07, 2024 (GLOBE NEWSWIRE) --  VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need, today announced financial results as of and for the three and nine months ended September 30, 2024 and provided a business update.

Read more at globenewswire.com